Best Practices and Research Advances in Thoracic Oncology: A Regional Series SE Asia Course 2: Immunotherapy in Lung Cancer-When to Incorporate Radiation Therapy

Video Transcription

Video Summary

Dr. Pranshu Mohindra discussed the integration of immunotherapy and radiation therapy in lung cancer treatment at the IASLC Regional Series for Southeast Asia. He explored radiation's role in various lung cancer stages: early-stage non-small cell lung cancer (NSCLC), locally advanced NSCLC, limited-stage small cell lung cancer, and metastatic disease. Stereotactic body radiation therapy (SPRT) is standard for early-stage inoperable NSCLC, with studies showing improved outcomes when combined with immunotherapy. For locally advanced NSCLC, consolidation immunotherapy post-chemoradiation is standard, but concurrent immunotherapy shows increased toxicity without benefit. In metastatic disease, radiation's combination with immunotherapy showed potential, yet SPRT in combination can increase pneumonitis risk. Study findings suggest using advanced radiation technologies to mitigate adverse effects. Dr. Mohindra highlighted the need for ongoing phase three trials to evaluate these combination therapies' efficacy and emphasized individualized patient care based on disease stage and available technology.

Asset Subtitle

Pranshu Mohindra, MD

Keywords

immunotherapy

radiation therapy

lung cancer

NSCLC

stereotactic body radiation therapy